SCHEMBL477871

SCHEMBL477871

CC(F)(F)CC[O]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7858150 0.80
SCHEMBL15022750 0.78
SCHEMBL166067 0.72
SCHEMBL5908680 0.71
SCHEMBL10126 0.69
SCHEMBL23555 0.69
SCHEMBL7857366 0.67
SCHEMBL20076863 0.67
SCHEMBL9775735 0.67
2,2-Difluoropentane SCHEMBL84483 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108218849-B Novel inhibitors 维沃永治疗公众有限公司 2022-03-01 CN claimed
EP-2970235-B1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2019-06-19 EP claimed
US-9512115-B2 Inhibitors PROBIODRUG AG (DE) 2016-12-06 US claimed
US-20160031869-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2016-02-04 US claimed
EP-2970235-A1 NOVEL INHIBITORS Probiodrug AG (DE) 2016-01-20 EP claimed
WO-2014140279-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2014-09-18 WO claimed
CN-108218849-B Novel inhibitors 维沃永治疗公众有限公司 2022-03-01 CN disclosed
US-20200283439-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES AbbVie Deutschland GmbH & Co. KG (DE) 2020-09-10 US disclosed
EP-3636651-A1 HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS AbbVie Deutschland GmbH & Co. KG (DE) 2020-04-15 EP disclosed
EP-2970235-B1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2019-06-19 EP disclosed
US-20190071443-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES AbbVie Deutschland GmbH & Co. KG (DE) 2019-03-07 US disclosed
US-20190048007-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES AbbVie Deutschland GmbH & Co. KG (DE) 2019-02-14 US disclosed
US-20180339996-A1 HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS AbbVie Deutschland GmbH & Co. KG (DE) 2018-11-29 US disclosed
WO-2006040177-A1 6-AMINO(AZA)INDANE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECPTOR ABBOTT GMBH & CO.KG (DE) 2006-04-20 WO disclosed
WO-2006040180-A1 AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2006-04-20 WO disclosed
WO-2006040176-A1 AZABICYCLOHEPTYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2006-04-20 WO disclosed
WO-2006040178-A1 ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO.KG (DE) 2006-04-20 WO disclosed
WO-2006040182-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2006-04-20 WO disclosed
US-6254941-B1 HIGH VOLTAGE HOLDING RATIO; LOW TEMPERATURE CHISSO CORPORATION (JP) 2001-07-03 US disclosed
EP-0950651-A1 FLUOROALKYLATED LIQUID-CRYSTAL COMPOUNDS, LIQUID-CRYSTAL COMPOSITIONS, AND LIQUID-CRYSTAL DISPLAY ELEMENTS CHISSO CORPORATION (JP) 1999-10-20 EP disclosed